Northfield looks to new $1.4m financing
This article was originally published in Clinica
Executive Summary
PolyHeme red blood cell substitute developer Northfield Laboratories says it has received a commitment from an institutional investor to purchase $1.4m-worth of its convertible preference stock. The stock is convertible into common stock at $0.265 per share. The unnamed investor has also received 5.4 million common stock warrants that are exercisable at $0.53 per share, six months after the closing (expected by March 18 2009). The Evanston, Illinois company will use the proceeds for general purposes and in connection with the regulatory review of PolyHeme.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.